CNTX
Context Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.36
−0.36%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-79.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 26, 2026 | Smith Karen L. · director | A-Award | 45,000 | $0.58 |
| Jun 26, 2026 | Walker Luke Nathaniel · director | A-Award | 45,000 | $0.58 |
| Jun 26, 2026 | Kantoff Philip W. · director | A-Award | 45,000 | $0.58 |
| Jun 26, 2026 | Pasternak Andy · director | A-Award | 45,000 | $0.58 |
| Jun 26, 2026 | Stacey Jennifer Evans · director | A-Award | 45,000 | $0.58 |
| Jun 26, 2026 | West Linda · director | A-Award | 45,000 | $0.58 |
| Feb 23, 2026 | Chagin Karen Deborah · officer: Chief Medical Officer | A-Award | 290,000 | $2.32 |
| Feb 23, 2026 | Minai-Azary Jennifer Lynn · officer: Chief Financial Officer | A-Award | 275,000 | $2.32 |
| Feb 23, 2026 | Levit Alex C. · officer: Chief Legal Officer, Corp. Sec | A-Award | 270,000 | $2.32 |
| Feb 23, 2026 | Lehr Martin A. · director, officer: Chief Executive Officer | A-Award | 815,000 | $2.32 |
| Jun 12, 2025 | Smith Karen L. · director | A-Award | 123,500 | $0.65 |
| Jun 12, 2025 | Kantoff Philip W. · director | A-Award | 123,500 | $0.65 |
| Jun 12, 2025 | West Linda · director | A-Award | 123,500 | $0.65 |
| Jun 12, 2025 | Walker Luke Nathaniel · director | A-Award | 123,500 | $0.65 |
| Jun 12, 2025 | Stacey Jennifer Evans · director | A-Award | 123,500 | $0.65 |
| Jun 12, 2025 | Pasternak Andy · director | A-Award | 138,900 | $0.65 |
| Jun 10, 2025 | Minai-Azary Jennifer Lynn · officer: Chief Financial Officer | Purchase | 40,010 | $0.64 |
| Jun 10, 2025 | Lehr Martin A. · director, officer: Chief Executive Officer | Purchase | 100,000 | $0.70 |
| Jun 10, 2025 | Levit Alex C. · officer: Chief Legal Officer, Corp. Sec | Purchase | 20,000 | $0.58 |
| Jun 9, 2025 | Chagin Karen Deborah · officer: Chief Medical Officer | A-Award | 153,000 | $0.70 |
| Feb 14, 2025 | Minai-Azary Jennifer Lynn · officer: Chief Financial Officer | A-Award | 371,800 | $0.81 |
| Feb 14, 2025 | Lehr Martin A. · director, officer: Chief Executive Officer | A-Award | 802,700 | $0.81 |
| Feb 14, 2025 | Dansky Ullmann Claudio · officer: Chief Medical Officer | A-Award | 174,960 | $0.81 |
| Feb 14, 2025 | Levit Alex C. · officer: Chief Legal Officer, Corp. Sec | A-Award | 349,900 | $0.81 |
| Jan 14, 2025 | Pasternak Andy · director | A-Award | 20,685 | $1.03 |
| Sep 5, 2024 | Smith Karen L. · director | A-Award | 19,315 | $2.43 |
| Sep 5, 2024 | Walker Luke Nathaniel · director | A-Award | 19,315 | $2.43 |
| Aug 1, 2024 | Dansky Ullmann Claudio · officer: Chief Medical Officer | A-Award | 202,170 | $2.23 |
| Jun 14, 2024 | West Linda · director | A-Award | 25,000 | $1.97 |
| Jun 14, 2024 | Kantoff Philip W. · director | A-Award | 25,000 | $1.97 |
Institutional positioning
13F filings over the trailing two quarters
New 27Increased 9Reduced 17Sold out 58
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BIOIMPACT CAPITAL LLC | Unchanged | 10,679,391 | May 15, 2026 |
| DEEP TRACK CAPITAL, LP | Unchanged | 7,419,355 | May 15, 2026 |
| NEXTECH INVEST, LTD. | Unchanged | 7,419,355 | May 15, 2026 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | New Position | 6,963,141 | May 14, 2026 |
| OCTAGON CAPITAL ADVISORS LP | New Position | 5,250,000 | May 15, 2026 |
| BLUE OWL CAPITAL HOLDINGS LP | Reduced | 5,089,015 | May 14, 2026 |
| AVIDITY PARTNERS MANAGEMENT LP | Reduced | 4,998,267 | May 28, 2026 |
| FRANKLIN RESOURCES INC | Reduced | 3,803,338 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3,431,953 | May 15, 2026 |
| MARSHALL WACE, LLP | Increased | 2,948,441 | May 15, 2026 |
| TCG CROSSOVER MANAGEMENT, LLC | New Position | 2,682,696 | May 15, 2026 |
| GREAT POINT PARTNERS LLC | Reduced | 2,238,496 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Reduced | 1,424,374 | May 15, 2026 |
| Squadron Capital Management LLC | New Position | 1,100,000 | May 15, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | New Position | 1,093,894 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 26, 2026